Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2009-06-30
2011-10-18
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018900, C514S021300, C514S021200, C435S069700, C530S300000, C530S350000, C530S351000
Reexamination Certificate
active
08039437
ABSTRACT:
Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer.
REFERENCES:
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 5283187 (1994-02-01), Aebischer et al.
patent: 7208151 (2007-04-01), Browning et al.
patent: 7285522 (2007-10-01), van Buskirk
patent: 7378089 (2008-05-01), Fathman
patent: WO 93/25673 (1993-12-01), None
patent: WO 96/07321 (1996-03-01), None
patent: WO 01/45730 (2001-06-01), None
patent: WO 03/086311 (2003-10-01), None
Nakayama et al., Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity, J. Exp. Med. 192(9):1373-1379, Nov. 6, 2000.
WO 2010005519 A1 srch rpt, Jan. 2010, World Intellect, Razmara M et al.
Razmara, M. et al, Fn14-TRIAL, a Chimeric Intercellular Signal Exchanger, Attenuates Experimental Autoimmune Encephalomyelitis, AJ Pathology, vol. 174, No. 2, Feb. 2009, pp. 460-474.
Hemmer, B. et al, Immunopathogenesis and immunotherapy of multiple sclerosis, Nature Clinical Practice Neurology, Apr. 2006, vol. 2, No. 4, 201-211.
Mackay F. et al., TNF ligands and receptors in autoimmunity: an update, Curr Opin Immunol 2002, 14:783-790.
Watts, T.H., TNF/TNFR Family Members in Costimulation of T Cell Responses, Annu. Rev. Immunol. 2005, 23:23-68.
Aktas O, et al., Death Ligands and Autoimmune Demyelination, The Neuroscientist, vol. 12, No. 4, 2006, 305-316.
Burkly L.C., et al., TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK/Fn14 pathway in health and disease, Cytokine 40 (2007) 1-16.
Winkles J.A., The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting, Nature Reviews, Drug Discovery, vol. 7, May 2008, 411-425.
Lamhamedi-Cherradi S.E., Critical Roles of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Type 1 Diabetes, Diabetes, vol. 52, Sep. 2003,2274-2278.
Cretney E, TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice, Immunology and Cell Biology (2005) vol. 83, 511-519.
Hirata S., Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells . . . J Immunology 2005, 174:1888-1897.
Wandinger K.P., TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis, Lancet, 2003, 361:2036-2043.
Huang J.H. et al, CTLA-4-Fas ligand functions as a trans signal converter protein in bridging antigen-presenting cells and T cells, Int'l Immunol vol. 13, No. 4, 2001, 529-539.
Elhalel M.D. et al., CTLA-4. FasL induces alloantigen-specific hyporesponsiveness, J Immunol 2003, 170:5842-5850.
Dranitzki-Elhalel M. et al, CTLA-4.FasL inhibits allogeneic responses in vivo, Cellular Immunol, vol. 239 (2006), 129-135.
Orbach A. et al, CTLA-4: FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals, J Immunol 2007, 179:7287-7294.
Brunschwig E.B. et al, Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function, J Immunol 1995, 155:5498-5505.
Liu F. et al, Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA, Gene Therapy (1999), vol. 6, 1258-1266.
Prasad R et al., 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis . . . , J Neurosci Research, 2006, 84:614-625.
Hilliard B et al., Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice:roles of NF-kappa B in the activation . . . , J Immunol 1999, 163:2937-2943.
Hymowitz S.G. et al., Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5, Molecular Cell, vol. 4, Oct. 1999, 563-571.
Marti-Renom M.A. et al, Comparative protein structure modeling of genes and genomes, Annu Rev Biophys Biomol Struct 2000, 29:291-325.
Isaacs J.D. et al, Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 . . . , J Immunol 1998, 161:3862-3869.
Hymowitz S.G. et al., Structures of APRIL-Receptor Complexes . . . , J Biol Chem, vol. 280, No. 8, Feb. 2005, 7218-7227.
Swaminathan P, Molecular structure, conformational analysis, and structure-activity studies of Dendrotoxin and its homologues . . . , J Med Chem 1996, vol. 39, 2141-2155.
Maecker H. et al., TWEAK attenuates the transition from innate to adaptive immunity, Cell, Dec. 2005, 123:931-944.
Saas P. et al., TWEAK stimulation of astrocytes and the proinflammatory consequences, GLIA 2000, 32:102-107.
Harada N. et al., Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells, Biochem Biophys Res Commun, vol. 299 (2002), 488-493.
Chicheportiche Y et al., Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes . . . , Arthritis Res 2002, 4:126-133.
Campbell S et al., Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells, J Immunol 2006, 176:1889-1898.
Xu H. et al., TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF, Biochem Biophys Res Commun, vol. 318 (2004), 422-427.
Ando T et al, TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic . . . , Arthritis Res Ther 2006, 8:R146.
Polavarapu R, Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit . . . , J Neurosci, Nov. 2005, 25(44):10094-10100.
Jakubowski A. et al, Dual role for TWEAK in angiogenic regulation, J Cell Sci 2002, vol. 115, 267-274.
Kirk S.L. et al., VEGF and vascular changes in chronic neuroinflammation, J Autoimmun 2003, vol. 21, 353-363.
Desplat-Jego S. et al., TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity, J Neuroimmunolgy 2002, vol. 133, 116-123.
Potrovita I. et al, Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration, J Neurosci, Sep. 2004, 24(38):8237-8244.
Mueller AM, Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis, J Neuroimmunol 2005, 159:55-65.
Ren X. et al, Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells, Cell Death Differ, 2007, vol. 14, 2076-2084.
Hilliard B et al., Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis, J Immunol 2001, 166:1314-1319.
Gold R. et al., Understanding pathogenesis and therapy of multiple sclerosis via animal models . . . , Brain 2006, vol. 129, 1953-1971.
Tykocinski, M.L. et al, New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints, Immunol Res 2003, 27/2-3:565-574.
Jin Y et al, Simultaneous stimulation of Fas-mediated apoptosis and blockade of costimulation prevent autoimmune diabetes in mice . . . , Gene Ther 2004, vol. 11, 982-991.
Vince J.E. et al, TWEAK shall inherit the earth, Cell Death Differ 2006, vol. 13, 1842-1844.
Cretney E. et al., TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer, Immunol Cell Biol 2006, vol. 84, 87-98.
Desplat-Jego S. et al., Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system . . . , Clin Immunol 2005, vol. 117, 15-23.
Kim Sh, TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages, Circulation J, Apr. 2004, vol. 68, 396-399.
Lamhamedi-Cherradi S.E. et al., Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice, Nat Immunol, Mar. 2003, vol. 4. No. 3, 255-260.
Song K et al, Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation & cell cycle progression, J Exp Med 2000 191:1095-1104.
Mi Q.S. et al, Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice, Di
Razmara Marjaneh
Tykocinski Mark L.
Kaufman Claire
Riverside Law LLP
Spector Lorraine
The Trustees of the University of Pennsylvania
LandOfFree
Fn14/TRAIL fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fn14/TRAIL fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fn14/TRAIL fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4292793